|
|||
2011-07-26 16:00:00 CEST 2011-07-26 16:00:32 CEST REGULATED INFORMATION Biotie Therapies - Major shareholder announcementsNotification according to Chapter 2, Section 10 of the Finnish Securities Market Act regarding changes in number of votesBIOTIE THERAPIES CORP. STOCK EXCHANGE RELEASE 26 July, 2011 at 5.00 p.m. Notification according to Chapter 2, Section 10 of the Finnish Securities Market Act regarding changes in number of votes Biotie Therapies Corp. ("Company" or "Biotie") has gained knowledge of a notification regarding changes in number of votes in accordance with Chapter 2, Section 9 of the Finnish Securities Markets Act, described below. The notification received by the Company concerns the changes in voting rights of Abingworth Management Limited (through Abingworth Bioventures IV LP and Abingworth Bioventures IV Executives LP) in the Company. The holdings of shares in the Company by Abingworth Management Limited (through Abingworth Bioventures IV LP and Abingworth Bioventures IV Executives LP) continue to be below 1/20, as previously. As a result of the changes in the number of voting rights announced on 18 March 2011, 6 June 2011 and 7 July 2011 the number of votes in the Company by Abingworth Management Limited (through Abingworth Bioventures IV LP and Abingworth Bioventures IV Executives LP) has decreased below 1/20. Name Number of Number of Number of (%) of Number of (%) of shares voting shares shares voting voting before rights after after rights rights before after after Abingworth Management Limited 16.693.258 16.693.258 16.693.258 4.66 16.693.258 4.66 (through Abingworth Bioventures IV LP and Abingworth Bioventures IV Executives LP) in total The number of voting rights and percentages presented above are calculated without taking into account the treasury shares held by the Company or its group companies. On the date hereof, the registered number of shares in Biotie is 387,594,457. Of these shares 11,880,224 are held by the Company or its group companies. Turku, 26 July 2011 Biotie Therapies Corp. Timo Veromaa President and CEO For further information, please contact: Virve Nurmi, Biotie Therapies Corp. tel. +358 2 274 8900 e-mail:virve.nurmi@biotie.com DISTRIBUTION NASDAQ OMX Helsinki Ltd Main Media www.biotie.com [HUG#1533503] |
|||
|